Scarica l'app Stockscreener
0.3241
2.56%
-0.0085
Dopo l'orario di chiusura:
.32
-0.0041
-1.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.3326
Aprire:
$0.3326
Volume 24 ore:
755.10K
Relative Volume:
0.34
Capitalizzazione di mercato:
$18.02M
Reddito:
$30.99M
Utile/perdita netta:
$-141.41M
Rapporto P/E:
-2.1607
EPS:
-0.15
Flusso di cassa netto:
$-118.12M
1 W Prestazione:
+11.76%
1M Prestazione:
-81.79%
6M Prestazione:
-78.54%
1 anno Prestazione:
-95.36%
Intervallo 1D:
$0.3177
$0.3326
Intervallo di 1 settimana:
$0.2875
$0.3458
Portata 52W:
$0.2603
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Nome
Marinus Pharmaceuticals Inc
Settore
Industria
Telefono
484-801-4670
Indirizzo
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-20 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-09-30 | Iniziato | Truist | Buy |
| 2020-07-01 | Iniziato | Cowen | Outperform |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-09 | Iniziato | Craig Hallum | Buy |
| 2019-12-20 | Iniziato | Oppenheimer | Outperform |
| 2019-03-05 | Ripresa | Jefferies | Buy |
| 2019-02-27 | Downgrade | Mizuho | Buy → Neutral |
| 2019-02-06 | Iniziato | Leerink Partners | Outperform |
| 2018-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-20 | Iniziato | Mizuho | Buy |
| 2018-02-15 | Iniziato | H.C. Wainwright | Buy |
| 2017-12-14 | Iniziato | Laidlaw | Buy |
| 2016-08-10 | Reiterato | Jefferies | Buy |
| 2016-06-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | Reiterato | Stifel | Buy |
| 2015-12-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2015-11-17 | Iniziato | Jefferies | Buy |
| 2015-10-30 | Reiterato | Oppenheimer | Outperform |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Marinus Pharmaceuticals Inc Borsa (MRNS) Ultime notizie
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
Marinus downgraded after setback to late-stage trial - MSN
Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN
TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN
Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal
Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN
Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks
Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha
HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices
Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues
JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus halts ganaxolone development after trial setback - Investing.com India
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India
Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK
Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia
Truist cuts Marinus Pharma to hold, drops price target - Investing.com
Truist cuts Marinus Pharma to hold, drops price target By Investing.com - Investing.com UK
Baird cuts Marinus Pharma target to $0.50 on failed study - Investing.com
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options - AOL
Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird - TipRanks
Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities - TipRanks
Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling - FiercePharma
Marinus Pharma stock plunges to 52-week low of $0.52 - Investing.com
Marinus hits record low after discontinuing development of rare disease drug - XM
Marinus Pharma stock plunges to 52-week low of $0.52 By Investing.com - Investing.com Canada
Marinus Pharmaceutical Shares Plumb New Depths After Study Failure - MarketWatch
Marinus Therapeutics plans layoffs, explores strategic alternatives as shares sink - The Business Journals
Marinus Pharma to explore options as rare disease drug fails trial - XM
Marinus notes TrustTSC trial misses primary endpoint, to evaluate alternatives - TipRanks
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire
Marinus Pharmaceuticals Issues Stock Options to New Employee - MSN
Marinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status Epilepticus - MSN
Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment - Clinical Trials Arena
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - BioSpace
MRNSMarinus Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Marinus reports positive phase 3 seizure treatment trial results - Investing.com
Marinus reports positive phase 3 seizure treatment trial results By Investing.com - Investing.com Australia
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - BioSpace
Marinus Pharmaceuticals secures new US patent for epilepsy drug By Investing.com - Investing.com Australia
Marinus Pharmaceuticals secures new US patent for epilepsy drug - Investing.com
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY - Business Wire
Examining Marinus Pharmaceuticals Inc (MRNS) more closely is necessary - US Post News
Marinus Pharmaceuticals Inc Azioni (MRNS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Marinus Pharmaceuticals Inc Azioni (MRNS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Aug 05 '24 |
Sale |
1.14 |
3,820 |
4,355 |
67,406 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Aug 05 '24 |
Sale |
1.13 |
3,621 |
4,092 |
60,263 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Aug 05 '24 |
Sale |
1.13 |
4,828 |
5,456 |
72,725 |
| Braunstein Scott | CHAIRMAN AND CEO |
Aug 05 '24 |
Sale |
1.13 |
12,145 |
13,724 |
298,667 |
| Braunstein Scott | CHAIRMAN AND CEO |
Mar 27 '24 |
Option Exercise |
4.28 |
50,000 |
214,000 |
273,512 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Feb 20 '24 |
Sale |
9.56 |
2,153 |
20,583 |
60,308 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Feb 20 '24 |
Sale |
9.57 |
1,894 |
18,126 |
52,966 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Feb 16 '24 |
Sale |
9.98 |
2,814 |
28,084 |
66,635 |
| Pfanstiel Steven | CFO AND COO |
Feb 16 '24 |
Sale |
9.97 |
3,092 |
30,827 |
71,697 |
| Braunstein Scott | CHAIRMAN AND CEO |
Feb 16 '24 |
Sale |
9.94 |
11,850 |
117,789 |
223,512 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):